Related Experiment Video
Updated: Jul 2, 2025
16:15
Mouse Kidney Transplantation: Models of Allograft Rejection
Published on: October 11, 2014
20.6K
Recurrent C3 glomerulopathy after kidney transplantation
Shota Obata1, Pedro A S Vaz de Castro2, Leonardo V Riella3
1Precision Immunology Institute, Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America.
Transplantation Reviews (Orlando, Fla.)
|February 27, 2024
Summary
C3 glomerulopathy (C3G) involves complement system dysregulation, often recurring after kidney transplants. New complement-targeting treatments show promise, but managing recurrent C3G remains challenging.
Area of Science:
- Immunology
- Nephrology
Background:
- The complement system is crucial for innate immunity and homeostasis.
- C3 glomerulopathy (C3G) is a rare kidney disease characterized by complement dysregulation.
- C3G has high recurrence rates post-kidney transplantation, impacting patient outcomes.
Purpose of the Study:
- To review the pathophysiology of C3G.
- To discuss current and emerging management strategies for C3G.
- To focus on the challenges of C3G recurrence after kidney transplantation.
Main Methods:
- Literature review of complement system biology in C3G.
- Analysis of current treatment modalities for C3G.
- Examination of post-transplantation recurrence data in C3G.
Main Results:
- Complement dysregulation is central to C3G pathogenesis.
- Standard treatments include mycophenolate mofetil and glucocorticoids.
- Emerging complement-targeted therapies demonstrate promising initial results.
Conclusions:
- Understanding complement pathways is key to C3G management.
- Recurrent C3G post-transplantation presents significant clinical challenges.
- Further research into novel therapies is needed for improved C3G outcomes.
